Program Offering and Eligibility

With the ENSPRYNG Co-pay Program, eligible, commercially insured patients pay as little as $5 per 30-day supply of ENSPRYNG. The program covers the rest of the patient's out-of-pocket costs, up to $20,000 in assistance per 12-month period.

There are no income requirements for the ENSPRYNG Co-pay Program.

TO BE ELIGIBLE FOR THE ENSPRYNG CO-PAY PROGRAM, PATIENTS MUST:
  • Be taking ENSPRYNG for an FDA-approved indication
  • Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance marketplaces
  • Be 18 years of age or older
  • Not be a government beneficiary and/or participant in a federal or state-funded health insurance program (eg, Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE)
  • Not be receiving assistance from the Genentech Patient Foundation or other charitable organizations for ENSPRYNG
  • Not live in a state where co-pay programs are prohibited

 

If a patient is not eligible for the ENSPRYNG Co-pay Program, there may be other options for financial assistance. Call (844) NSPRYNG (844-677-7964) or visit Genentech-Access.com/ENSPRYNG to learn more.

Indication and Important Safety Information

ENSPRYNG Important Safety Information

Indication

ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Contraindications

ENSPRYNG is contraindicated in patients with a known hypersensitivity to satralizumab or any of the inactive ingredients, an active hepatitis B infection, or active or untreated latent tuberculosis.

Warnings and Precautions

Infections
Delay ENSPRYNG administration in patients with an active infection until the infection is resolved. Vaccination with live or live attenuated vaccines is not recommended during treatment.

Elevated Liver Enzymes
Monitor ALT and AST levels during treatment; interruption of ENSPRYNG may be required.

Decreased Neutrophil Counts
Monitor neutrophils during treatment.

Most Common Adverse Reactions

The most common adverse reactions (≥15% in either trial) were nasopharyngitis (31%), headache (27%), upper respiratory tract infection (19%), rash (17%), arthralgia (17%), extremity pain (15%), gastritis (15%), fatigue (15%), and nausea (15%).

For additional safety information, please see the full Prescribing Information and Medication Guide.